{"id":384818,"date":"2020-11-19T07:25:07","date_gmt":"2020-11-19T12:25:07","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384818"},"modified":"2020-11-19T07:25:07","modified_gmt":"2020-11-19T12:25:07","slug":"aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/","title":{"rendered":"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SINGAPORE, Nov.  19, 2020  (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32<sup>nd<\/sup> Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020.<\/p>\n<p>A replay of the pre-recorded fireside chat will be available from November 23, 2020 in the Investor Relations section of ASLAN\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OrHlgn3nqPSyM_-Mr_g2Evcv_wLoTQaflnWD9KccLPspetVbK3n6sX_LAlzm0kB1Vamrr2TFGMhsrSIgOAPimli7mZVsKi7wB2VWzfHt6Hg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.aslanpharma.com<\/a>. The replay will be available for 30 days. ASLAN will be participating in 1&#215;1 meetings on 30 November to 3 December 2020, meetings may be requested exclusively via Piper Sandler.<\/p>\n<p>\n        <strong>M<\/strong><br \/>\n        <strong>edia<\/strong><br \/>\n        <strong> and IR<\/strong><br \/>\n        <strong> contacts<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Emma Thompson<\/strong><br \/>\n            <br \/>Spurwing Communications<br \/>Tel: +65 6751 2021<br \/>Email: <a href=\"mailto:ASLAN@spurwingcomms.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ASLAN@spurwingcomms.com<\/a><\/td>\n<td style=\"vertical-align: top\">\n            <strong>Robert Uhl<\/strong><br \/>\n            <br \/>Westwicke Partners<br \/>Tel: +1 858 356 5932 <br \/>Email: <a href=\"mailto:robert.uhl@westwicke.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">robert.uhl@westwicke.com<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About ASLAN Pharmaceuticals<\/strong><br \/>\n        <br \/>ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. Led by a senior management team with extensive experience in global development and commercialisation, ASLAN has a clinical portfolio comprised of a first-in-class monoclonal therapy, ASLAN004, that is being developed in atopic dermatitis and other immunology indications, and ASLAN003, which it plans to develop for autoimmune disease. For additional information please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OrHlgn3nqPSyM_-Mr_g2EtIotXTnZP32aciXqhs4-AGeB5eSqwJAkB9VdzIkoA9fQb72CVfRrYZfmYHtJhL1HezPnCtu6-iMsO0_VBO7oAA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.aslanpharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward <\/strong><br \/>\n        <strong>l<\/strong><br \/>\n        <strong>ooking <\/strong><br \/>\n        <strong>s<\/strong><br \/>\n        <strong>tatements<\/strong>\n      <\/p>\n<p>This release and the accompanying financial information, if any, contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of ASLAN Pharmaceuticals Limited and\/or its affiliates (the &#8220;Company&#8221;). These forward-looking statements may include, but are not limited to, statements regarding the Company\u2019s business strategy and clinical development plans; the Company\u2019s plans to develop and commercialise ASLAN004 and ASLAN003; the safety and efficacy of ASLAN004 and ASLAN003; the Company\u2019s plans and expected timing with respect to clinical trials and clinical trial results for ASLAN004 and ASLAN003; the potential for ASLAN004 to deliver a best-in-disease treatment for people with atopic dermatitis; the potential for ASLAN003 to have a best in class profile as a potent oral DHODH inhibitor targeting autoimmune indications; the potential for ASLAN003 to be a treatment for COVID-19 and other viral infections; and the scale of the unmet need in atopic dermatitis. The Company\u2019s estimates, projections and other forward-looking statements are based on management&#8217;s current assumptions and expectations of future events and trends, which affect or may affect the Company\u2019s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of many risks and uncertainties, which include, unexpected safety or efficacy data observed during preclinical or clinical studies; clinical site activation rates or clinical trial enrolment rates that are lower than expected; the impact of the COVID-19 pandemic on the Company\u2019s business and the global economy; general market conditions; changes in the competitive landscape; and the Company\u2019s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company\u2019s US Securities and Exchange Commission filings and reports (Commission File No. 001-38475), including the Company\u2019s Annual Report on Form 20-F filed with the US Securities and Exchange Commission on April 16, 2020.\u00a0\u00a0<\/p>\n<p>All statements other than statements of historical fact are forward-looking statements. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201ccould,\u201d \u201cwill,\u201d \u201caim,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cplan,\u201d or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/75bc38df-b9ca-4e8b-917c-37554795131b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020. A replay of the pre-recorded fireside chat will be available from November 23, 2020 in the Investor Relations section of ASLAN\u2019s website at www.aslanpharma.com. The replay will be available for 30 days. ASLAN will be participating in 1&#215;1 meetings on 30 November to 3 December 2020, meetings may be requested exclusively via Piper Sandler. M edia and IR contacts Emma &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384818","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020. A replay of the pre-recorded fireside chat will be available from November 23, 2020 in the Investor Relations section of ASLAN\u2019s website at www.aslanpharma.com. The replay will be available for 30 days. ASLAN will be participating in 1&#215;1 meetings on 30 November to 3 December 2020, meetings may be requested exclusively via Piper Sandler. M edia and IR contacts Emma &hellip; Continue reading &quot;ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T12:25:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference\",\"datePublished\":\"2020-11-19T12:25:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/\"},\"wordCount\":658,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/\",\"name\":\"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=\",\"datePublished\":\"2020-11-19T12:25:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference - Market Newsdesk","og_description":"SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from 30 November to 3 December 2020. A replay of the pre-recorded fireside chat will be available from November 23, 2020 in the Investor Relations section of ASLAN\u2019s website at www.aslanpharma.com. The replay will be available for 30 days. ASLAN will be participating in 1&#215;1 meetings on 30 November to 3 December 2020, meetings may be requested exclusively via Piper Sandler. M edia and IR contacts Emma &hellip; Continue reading \"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T12:25:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference","datePublished":"2020-11-19T12:25:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/"},"wordCount":658,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/","name":"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=","datePublished":"2020-11-19T12:25:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTIwNCMzODM1Njg0IzIwOTU0OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384818"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384818\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}